Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Drug

Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson

Fineline Cube Sep 22, 2023

Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...

Company Deals

Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases

Fineline Cube Sep 22, 2023

Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum...

Company Drug

Mabwell Bioscience’s 9MW3011 Earns US FDA Fast Track Designation for Polycythemia Vera Treatment

Fineline Cube Sep 22, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Medical Device

Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit

Fineline Cube Sep 22, 2023

Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced...

Company Deals

Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement

Fineline Cube Sep 21, 2023

Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...

Company Deals

Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery

Fineline Cube Sep 21, 2023

German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...

Company Drug

Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from...

Company Drug

Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment

Fineline Cube Sep 21, 2023

US-based Organon (NYSE: OGN) has announced that it has received market approval from the National...

Company

WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi

Fineline Cube Sep 21, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Policy / Regulatory

CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications

Fineline Cube Sep 21, 2023

The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference...

Company Deals

Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...

Company Deals

Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline

Fineline Cube Sep 21, 2023

Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...

Company Drug

Hainan Poly Pharm Submits DMF for Tecovirimat API to US FDA

Fineline Cube Sep 21, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced the filing of a Drug...

Company Legal / IP

South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening

Fineline Cube Sep 21, 2023

The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...

Company Drug

Tonghua Golden-Horse’s Octohydroaminoacridine Succinate Meets Phase III Endpoints in Alzheimer’s Disease

Fineline Cube Sep 21, 2023

China-based Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) has announced positive results from its...

Policy / Regulatory

China’s NHC Expands Rare Disease List, Includes 21 Cancer Types

Fineline Cube Sep 21, 2023

The National Health Commission (NHC) of China has released an updated national list of rare...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Completes Phase III Safety Observation

Fineline Cube Sep 21, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the successful completion of the 7-day...

Company Drug Medical Device

Jiangsu Yahong’s Cevira Meets Primary Endpoint in Phase III Cervical HSIL Study

Fineline Cube Sep 21, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, has...

Company Drug

Hybio Pharmaceutical Gets NMPA Approval for COVID-19 Nasal Spray HY3000

Fineline Cube Sep 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has received approval from the National Medical Products...

Company Drug

GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted regulatory approval to GlaxoSmithKline (GSK; NYSE:...

Posts pagination

1 … 460 461 462 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.